The Effectiveness of Silodosin for Nocturnal Polyuria in Elderly Men With Benign Prostatic Hyperplasia: A Multicenter Study

被引:13
|
作者
Kim, Young Won [1 ]
Park, Jinsung [2 ]
Chung, Hong [3 ]
Kim, Hong-Wook [4 ]
Kim, Hyung Joon [4 ]
Jung, Jae Hung [5 ]
Kim, Won Tae [1 ]
机构
[1] Chungbuk Natl Univ, Coll Med, Dept Urol, Cheongju 28644, South Korea
[2] Eulji Univ, Sch Med, Dept Urol, Daejeon, South Korea
[3] Konkuk Univ, Sch Med, Dept Urol, Chungju, South Korea
[4] Konyang Univ, Coll Med, Dept Urol, Daejeon, South Korea
[5] Yonsei Univ, Wonju Coll Med, Dept Urol, Wonju, South Korea
关键词
Nocturia; Adrenergic alpha-Antagonists; Prostatic Hyperplasia; URINARY-TRACT SYMPTOMS; DOUBLE-BLIND; SLEEP; DESMOPRESSIN; QUALITY; EFFICACY;
D O I
10.5213/inj.2015.19.3.190
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: To investigate improvement in nocturia and nocturnal polyuria in nocturnal polyuria patients after silodosin administration by using a 3-day frequency volume chart. Methods: This was a prospective multicenter study. We enrolled nocturnal polyuria patients (nocturnal polyuria index [NPi] >0.33), aged >= 60 years, diagnosed with the 3-day frequency volume charts of patients with benign prostatic hyperplasia taking alpha-blockers. Of the 54 patients, 30 (55.6%) completed the study according to the study protocol (per-protocol group), and 24 dropped out (dropout group). Results: Of the 24 patients in the dropout group, 5 withdrew consent due to side effects or lack of efficacy, 7 were lost to follow-up at 4 weeks, 8 were lost to follow-up at 12 weeks, and 4 dropped out due to failure to complete 3-day frequency volume charts at 12 weeks. In the per-protocol group, there was significant improvement in the International Prostate Symptom Score (IPSS), especially question numbers 1, 3, 4, 5, 6, 7, and the quality of life question (P=0.001, P = 0.007, P<0.001, P=0.003, P=0.049, P<0.001, and P<0.001, respectively). The Leeds sleep evaluation questionnaire (LSEQ) score for the sleep question improved from 64.36 to 70.43 (P = 0.039). The NPi reduced from 0.4005 to 0.3573 (P =0.027); however, in many cases, there was no improvement in nocturnal polyuria itself. In intention-to-treat analysis, there were significant improvements in IPSS and LSEQ in 45 patients. Conclusions: In elderly nocturnal polyuria patients, silodosin monotherapy exhibits good efficacy in improving nocturia and nocturnal polyuria; however, the mean NPi was still >0.33. Considering the high dropout rate of our study due to no implementation of 3-day frequency volume charts, prospective and large-scale studies are needed to confirm our results.
引用
收藏
页码:190 / 196
页数:7
相关论文
共 50 条
  • [11] Comparison of Silodosin Monotherapy vs Silodosin With Tadalafil Add-on Therapy in Patients With Benign Prostatic Hyperplasia
    Yoshida, Takashi
    Kinoshita, Hidefumi
    Shimada, Seiji
    Taguchi, Makoto
    Matsuda, Tadashi
    UROLOGY, 2017, 106 : 153 - 159
  • [12] Impact of desmopressin on nocturia due to nocturnal polyuria in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH)
    Richard Berges
    Klaus Höfner
    Michael Gedamke
    Matthias Oelke
    World Journal of Urology, 2014, 32 : 1163 - 1170
  • [13] Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: A randomized controlled trial
    Pande, Satabdi
    Hazra, Avijit
    Kundu, Anup Kumar
    INDIAN JOURNAL OF PHARMACOLOGY, 2014, 46 (06) : 601 - 607
  • [14] Silodosin: A Review of Its Use in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia
    Keating, Gillian M.
    DRUGS, 2015, 75 (02) : 207 - 217
  • [15] Efficacy of Desmopressin to Treat Nocturnal Polyuria in Elderly Men: Effects on Sleep Quality
    Kim, Sun-Ouck
    Yu, Ho Song
    Kwon, Dongdeuk
    UROLOGIA INTERNATIONALIS, 2016, 96 (04) : 438 - 442
  • [16] Nocturia Potentially Influences Maintenance of Sexual Function in Elderly Men with Benign Prostatic Hyperplasia
    Ishizuka, Osamu
    Matsuyama, Hideyasu
    Sakai, Hideki
    Matsubara, Akio
    Nagaoka, Akira
    Takahashi, Satoru
    Takeda, Masayuki
    Ozono, Seiichiro
    Shiroki, Ryoichi
    Shuin, Taro
    Hara, Isao
    Kakizaki, Hidehiro
    Tsukamoto, Taiji
    Yamanishi, Tomonori
    Yokoyama, Osamu
    Kakehi, Yoshiyuki
    Nishizawa, Osamu
    LUTS-LOWER URINARY TRACT SYMPTOMS, 2013, 5 (02) : 75 - 81
  • [17] Conversion to Silodosin in Men on Conventional α1-Blockers for Symptomatic Benign Prostatic Hyperplasia
    Tanaka, Masahiko
    Niimi, Aya
    Tomita, Kyoichi
    Homma, Yukio
    LUTS-LOWER URINARY TRACT SYMPTOMS, 2010, 2 (01) : 11 - 15
  • [18] Study of Quality of life in Patients with Benign Prostatic Hyperplasia under Treatment with Silodosin
    Castro-Diaz, D.
    Callejo, D.
    Cortes, X.
    Perez, M.
    ACTAS UROLOGICAS ESPANOLAS, 2014, 38 (06): : 361 - 366
  • [19] Evaluation of Silodosin and Pelvic Floor Muscle Training in Men with Benign Prostatic Hyperplasia and Overactive Bladder (Silodosing) Study Protocol (Spirit Compliant)
    Hagovska, Magdalena
    Svihra, Jan
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (21)
  • [20] Silodosin for the Treatment of Benign Prostatic Hyperplasia: Pharmacology and Cardiovascular Tolerability
    Lepor, Herbert
    Hill, Lawrence A.
    PHARMACOTHERAPY, 2010, 30 (12): : 1303 - 1312